English

SUNESIS PHARMACEUTICALS INC

EDGAR

SNSS Quarterly report (10-Q) · filed 2024-11-13

99 filing records in this dataset, filed from 2005-11-14 to 2024-11-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2020 Q4 · USD

Exact inputs and evidence

Revenue: 120000 USD Source
Revenue: 120000 USD Source

Operating cash flow

-4.54 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -16054000 USD Source
Operating Cash Flow: -11513000 USD Source

Free cash flow

-4.54 million USD

2020 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -16054000 USD Source
Operating Cash Flow: -11513000 USD Source
Capital Expenditure: 55000 USD Source
Capital Expenditure: 55000 USD Source

Cash and cash equivalents: 13.1 million USD 2024-09-30 Source
Exact value

13127000 USD
Long-term debt including current maturities: 16.9 million USD 2024-09-30 Source
Exact value

16911000 USD
Shares outstanding: 39.7 million shares 2024-09-30 Source
Exact value

39744222 shares

Reported share-count change

2.90% · 1.12 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

38624553 shares · 2023-09-30· Source
39744222 shares · 2024-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

120 thousand USD

2020-01-01 – 2020-12-31

Exact inputs and evidence

Revenue: 120000 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 120000 USD · 2020-01-01 – 2020-06-30 Source
Revenue: 120000 USD · 2020-01-01 – 2020-03-31 Source
Revenue: 120000 USD · 2020-01-01 – 2020-09-30 Source
Revenue: 120000 USD · 2020-01-01 – 2020-06-30 Source
Revenue: 120000 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 120000 USD · 2020-01-01 – 2020-09-30 Source

Net income

-43.3 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Net income: -51058000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -37293000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -9141000 USD · 2024-01-01 – 2024-03-31 Source
Net income: -9830000 USD · 2024-04-01 – 2024-06-30 Source
Net income: -10553000 USD · 2024-07-01 – 2024-09-30 Source

Operating cash flow

-34.8 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Operating cash flow: -39892000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -29865000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -7849000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -17676000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -7849000 USD · 2024-01-01 – 2024-03-31 Source
Operating cash flow: -24769000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -17676000 USD · 2024-01-01 – 2024-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-11-13.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2020-12-31
Operating income: 11 of 11 periods available· newest 2023-12-31
Net income: 11 of 11 periods available· newest 2023-12-31
Operating cash flow: 11 of 11 periods available· newest 2023-12-31
Capital expenditure: 6 of 11 periods available· newest 2023-12-31
Total assets: 11 of 11 periods available· newest 2023-12-31
Total liabilities: 6 of 11 periods available· newest 2023-12-31
Current assets: 11 of 11 periods available· newest 2023-12-31
Current liabilities: 11 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2023-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 1.86 million

Prior period

−USD 49.2 million

2022-01-01 – 2022-12-31
Current period

−USD 51.06 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-51058000 − -49197000 = -1861000 USD

-49197000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-51058000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Year-over-year change in Net income: -1861000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -51058000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1572456 Filing: 000095017024027982 Input fundies:NetIncome: -49197000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1573741 Filing: 000095017024027982
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 4.44 million

Prior period

−USD 35.46 million

2022-01-01 – 2022-12-31
Current period

−USD 39.89 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-39892000 − -35457000 = -4435000 USD

-35457000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-39892000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Year-over-year change in Operating cash flow: -4435000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -39892000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1602364 Filing: 000095017024027982 Input fundies:OperatingCashFlow: -35457000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1603868 Filing: 000095017024027982
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+206.7%

Prior period

USD 45,000

2022-01-01 – 2022-12-31
Current period

USD 138,000

2023-01-01 – 2023-12-31

Exact inputs and evidence

138000 − 45000 = 93000 USD

45000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
138000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Year-over-year change in Capital expenditure: 93000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 138000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1607396 Filing: 000095017024027982 Input fundies:CapitalExpenditure: 45000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1608689 Filing: 000095017024027982
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 120,000 100% of revenue
Operating costs Derived USD 18.94 million 15,779% of revenue
Operating income −USD 18.82 million −15,679% of revenue
Tax, interest and other Derived USD 202,000 168% of revenue
Net income −USD 19.02 million −15,848% of revenue

Cash

Operating cash flow −USD 16.05 million −13,378% of revenue
Capital expenditure USD 55,000 46% of revenue
Free cash flow Derived −USD 16.11 million −13,424% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 886% of revenue.
2015 Operating loss: operating costs were 1,384% of revenue.
2016 Operating loss: operating costs were 1,538% of revenue.
2017 Operating loss: operating costs were 5,245% of revenue.
2018 Operating loss: operating costs were 10,948% of revenue.
2019 Operating loss: operating costs were 1,223% of revenue.
2020 Operating loss: operating costs were 15,779% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	5734000	50777000 Derived	-45043000	-2041000 Derived	-43002000	-43229000 Derived	Source 2014-01-01 – 2014-12-31: 5734000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -45043000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -43002000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -43181000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 48000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	3061000	42363000 Derived	-39302000	-2626000 Derived	-36676000	Unavailable	Source 2015-01-01 – 2015-12-31: 3061000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -39302000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -36676000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -38731000 USD Inspect Operating Cash Flow Open source
2016 2016-01-01 – 2016-12-31	2536000	38996000 Derived	-36460000	1563000 Derived	-38023000	Unavailable	Source 2016-01-01 – 2016-12-31: 2536000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -36460000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -38023000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -36962000 USD Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	669000	35088000 Derived	-34419000	1039000 Derived	-35458000	-36168000 Derived	Source 2017-01-01 – 2017-12-31: 669000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -34419000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -35458000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -36142000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 26000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	237000	25947000 Derived	-25710000	905000 Derived	-26615000	Unavailable	Source 2018-01-01 – 2018-12-31: 237000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -25710000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -26615000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -24404000 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	2073000	25361000 Derived	-23288000	42000 Derived	-23330000	Unavailable	Source 2019-01-01 – 2019-12-31: 2073000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -23288000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -23330000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -22185000 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	120000	18935000 Derived	-18815000	202000 Derived	-19017000	-16109000 Derived	Source 2020-01-01 – 2020-12-31: 120000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -18815000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -19017000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -16054000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 55000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 120K 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	7956000	Revenue: 7956000 Open source
20142014-12-31	Revenue	5734000	Revenue: 5734000 Open source
20152015-12-31	Revenue	3061000	Revenue: 3061000 Open source
20162016-12-31	Revenue	2536000	Revenue: 2536000 Open source
20172017-12-31	Revenue	669000	Revenue: 669000 Open source
20182018-12-31	Revenue	237000	Revenue: 237000 Open source
20192019-12-31	Revenue	2073000	Revenue: 2073000 Open source
20202020-12-31	Revenue	120000	Revenue: 120000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-94.2% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 7956000 Open source
20142014-12-31	Year over year	-27.9%	Revenue: 5734000 Open source Revenue: 7956000 Open source
20152015-12-31	Year over year	-46.6%	Revenue: 3061000 Open source Revenue: 5734000 Open source
20162016-12-31	Year over year	-17.2%	Revenue: 2536000 Open source Revenue: 3061000 Open source
20172017-12-31	Year over year	-73.6%	Revenue: 669000 Open source Revenue: 2536000 Open source
20182018-12-31	Year over year	-64.6%	Revenue: 237000 Open source Revenue: 669000 Open source
20192019-12-31	Year over year	774.7%	Revenue: 2073000 Open source Revenue: 237000 Open source
20202020-12-31	Year over year	-94.2%	Revenue: 120000 Open source Revenue: 2073000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -15,679.2% 2020

Net margin -15,847.5% 2020

Free cash flow margin -13,424.2% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-399.4%	Operating Income: -31773000 Open source Revenue: 7956000 Open source
20142014-12-31	Operating margin	-785.5%	Operating Income: -45043000 Open source Revenue: 5734000 Open source
20152015-12-31	Operating margin	-1,284%	Operating Income: -39302000 Open source Revenue: 3061000 Open source
20162016-12-31	Operating margin	-1,437.7%	Operating Income: -36460000 Open source Revenue: 2536000 Open source
20172017-12-31	Operating margin	-5,144.8%	Operating Income: -34419000 Open source Revenue: 669000 Open source
20182018-12-31	Operating margin	-10,848.1%	Operating Income: -25710000 Open source Revenue: 237000 Open source
20192019-12-31	Operating margin	-1,123.4%	Operating Income: -23288000 Open source Revenue: 2073000 Open source
20202020-12-31	Operating margin	-15,679.2%	Operating Income: -18815000 Open source Revenue: 120000 Open source
20132013-12-31	Net margin	-434.9%	Net Income: -34598000 Open source Revenue: 7956000 Open source
20142014-12-31	Net margin	-749.9%	Net Income: -43002000 Open source Revenue: 5734000 Open source
20152015-12-31	Net margin	-1,198.2%	Net Income: -36676000 Open source Revenue: 3061000 Open source
20162016-12-31	Net margin	-1,499.3%	Net Income: -38023000 Open source Revenue: 2536000 Open source
20172017-12-31	Net margin	-5,300.1%	Net Income: -35458000 Open source Revenue: 669000 Open source
20182018-12-31	Net margin	-11,230%	Net Income: -26615000 Open source Revenue: 237000 Open source
20192019-12-31	Net margin	-1,125.4%	Net Income: -23330000 Open source Revenue: 2073000 Open source
20202020-12-31	Net margin	-15,847.5%	Net Income: -19017000 Open source Revenue: 120000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 7956000 Open source
20142014-12-31	Free cash flow margin	-753.9%	Revenue: 5734000 Open source Operating Cash Flow: -43181000 Open source Capital Expenditure: 48000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 3061000 Open source Operating Cash Flow: -38731000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 2536000 Open source Operating Cash Flow: -36962000 Open source
20172017-12-31	Free cash flow margin	-5,406.3%	Revenue: 669000 Open source Operating Cash Flow: -36142000 Open source Capital Expenditure: 26000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 237000 Open source Operating Cash Flow: -24404000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 2073000 Open source Operating Cash Flow: -22185000 Open source
20202020-12-31	Free cash flow margin	-13,424.2%	Revenue: 120000 Open source Operating Cash Flow: -16054000 Open source Capital Expenditure: 55000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -16.1M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	Not reported	No source recorded
20142014-12-31	Operating cash flow	-43181000	Operating Cash Flow: -43181000 Open source
20152015-12-31	Operating cash flow	-38731000	Operating Cash Flow: -38731000 Open source
20162016-12-31	Operating cash flow	-36962000	Operating Cash Flow: -36962000 Open source
20172017-12-31	Operating cash flow	-36142000	Operating Cash Flow: -36142000 Open source
20182018-12-31	Operating cash flow	-24404000	Operating Cash Flow: -24404000 Open source
20192019-12-31	Operating cash flow	-22185000	Operating Cash Flow: -22185000 Open source
20202020-12-31	Operating cash flow	-16054000	Operating Cash Flow: -16054000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -16.1M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	Unavailable	No source recorded
20142014-12-31	Free cash flow	-43229000	Operating Cash Flow: -43181000 Open source Capital Expenditure: 48000 Open source
20152015-12-31	Free cash flow	Unavailable	Operating Cash Flow: -38731000 Open source
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: -36962000 Open source
20172017-12-31	Free cash flow	-36168000	Operating Cash Flow: -36142000 Open source Capital Expenditure: 26000 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -24404000 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -22185000 Open source
20202020-12-31	Free cash flow	-16109000	Operating Cash Flow: -16054000 Open source Capital Expenditure: 55000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.9% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	Total Assets: 40525000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 44246000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 47002000 Open source
2016-12-31	Liabilities / assets	Not reported	Total Assets: 43234000 Open source
20172017-12-31	Liabilities / assets	37.3%	Total Liabilities: 12790000 Open source Total Assets: 34334000 Open source
20182018-12-31	Liabilities / assets	73.9%	Total Liabilities: 11331000 Open source Total Assets: 15324000 Open source
20192019-12-31	Liabilities / assets	26%	Total Liabilities: 9697000 Open source Total Assets: 37240000 Open source
20202020-12-31	Liabilities / assets	6.9%	Total Liabilities: 3310000 Open source Total Assets: 48305000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.51× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	1.19×	Current Assets: 40492000 Open source Current Liabilities: 33972000 Open source
20142014-12-31	Current assets / current liabilities	1.59×	Current Assets: 44204000 Open source Current Liabilities: 27881000 Open source
20152015-12-31	Current assets / current liabilities	2.47×	Current Assets: 46988000 Open source Current Liabilities: 18999000 Open source
20162016-12-31	Current assets / current liabilities	3.95×	Current Assets: 43231000 Open source Current Liabilities: 10939000 Open source
20172017-12-31	Current assets / current liabilities	2.6×	Current Assets: 32933000 Open source Current Liabilities: 12678000 Open source
20182018-12-31	Current assets / current liabilities	1.34×	Current Assets: 15200000 Open source Current Liabilities: 11323000 Open source
20192019-12-31	Current assets / current liabilities	3.86×	Current Assets: 36322000 Open source Current Liabilities: 9416000 Open source
20202020-12-31	Current assets / current liabilities	7.51×	Current Assets: 47199000 Open source Current Liabilities: 6284000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 43 million Exact value Exact value: -43002000 USD 2014-01-01 – 2014-12-31: -43002000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2014-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -43002000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43002000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459017003862/snss-20161231.xml#108326 Filing: 000156459017003862 The citation records this snapshot. The page link may show a newer release later.	−USD 43.18 million Exact value Exact value: -43181000 USD 2014-01-01 – 2014-12-31: -43181000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2014-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -43181000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43181000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459017003862/snss-20161231.xml#150701 Filing: 000156459017003862 The citation records this snapshot. The page link may show a newer release later.	USD 48,000 Exact value Exact value: 48000 USD 2014-01-01 – 2014-12-31: 48000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2014-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 48000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 48000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459017003862/snss-20161231.xml#150953 Filing: 000156459017003862 The citation records this snapshot. The page link may show a newer release later.	−USD 43.23 million Calculation and evidence -43181000 − 48000 USD Exact free cash flow: -43229000 USD 2014-01-01 – 2014-12-31: -43181000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 48000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2014-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -43229000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43181000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459017003862/snss-20161231.xml#150701 Filing: 000156459017003862 Input fundies:CapitalExpenditure: 48000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459017003862/snss-20161231.xml#150953 Filing: 000156459017003862 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 36.68 million Exact value Exact value: -36676000 USD 2015-01-01 – 2015-12-31: -36676000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2015-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -36676000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36676000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459018005146/snss-20171231.xml#116580 Filing: 000156459018005146 The citation records this snapshot. The page link may show a newer release later.	−USD 38.73 million Exact value Exact value: -38731000 USD 2015-01-01 – 2015-12-31: -38731000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2015-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -38731000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -38731000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459018005146/snss-20171231.xml#160747 Filing: 000156459018005146 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 38.02 million Exact value Exact value: -38023000 USD 2016-01-01 – 2016-12-31: -38023000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2016-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -38023000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38023000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459018005146/snss-20171231.xml#116426 Filing: 000156459018005146 The citation records this snapshot. The page link may show a newer release later.	−USD 36.96 million Exact value Exact value: -36962000 USD 2016-01-01 – 2016-12-31: -36962000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2016-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -36962000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36962000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459018005146/snss-20171231.xml#160495 Filing: 000156459018005146 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 35.46 million Exact value Exact value: -35458000 USD 2017-01-01 – 2017-12-31: -35458000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2017-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -35458000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35458000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/snss-20181231.xml#106314 Filing: 000156459019006828 The citation records this snapshot. The page link may show a newer release later.	−USD 36.14 million Exact value Exact value: -36142000 USD 2017-01-01 – 2017-12-31: -36142000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2017-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -36142000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36142000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/snss-20181231.xml#131889 Filing: 000156459019006828 The citation records this snapshot. The page link may show a newer release later.	USD 26,000 Exact value Exact value: 26000 USD 2017-01-01 – 2017-12-31: 26000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2017-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 26000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/snss-20181231.xml#132101 Filing: 000156459019006828 The citation records this snapshot. The page link may show a newer release later.	−USD 36.17 million Calculation and evidence -36142000 − 26000 USD Exact free cash flow: -36168000 USD 2017-01-01 – 2017-12-31: -36142000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 26000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2017-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -36168000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36142000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/snss-20181231.xml#131889 Filing: 000156459019006828 Input fundies:CapitalExpenditure: 26000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459019006828/snss-20181231.xml#132101 Filing: 000156459019006828 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 26.62 million Exact value Exact value: -26615000 USD 2018-01-01 – 2018-12-31: -26615000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2018-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -26615000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26615000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459020009783/snss-20191231.xml#119485 Filing: 000156459020009783 The citation records this snapshot. The page link may show a newer release later.	−USD 24.4 million Exact value Exact value: -24404000 USD 2018-01-01 – 2018-12-31: -24404000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2018-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -24404000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24404000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459020009783/snss-20191231.xml#144887 Filing: 000156459020009783 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 23.33 million Exact value Exact value: -23330000 USD 2019-01-01 – 2019-12-31: -23330000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2019-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -23330000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23330000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459021007784/snss-20201231.xml#104432 Filing: 000156459021007784 The citation records this snapshot. The page link may show a newer release later.	−USD 22.19 million Exact value Exact value: -22185000 USD 2019-01-01 – 2019-12-31: -22185000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2019-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -22185000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22185000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000156459021007784/snss-20201231.xml#127507 Filing: 000156459021007784 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 19.02 million Exact value Exact value: -19017000 USD 2020-01-01 – 2020-12-31: -19017000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2020-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -19017000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19017000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017022003991/virx-20211231.htm#2175353 Filing: 000095017022003991 The citation records this snapshot. The page link may show a newer release later.	−USD 16.05 million Exact value Exact value: -16054000 USD 2020-01-01 – 2020-12-31: -16054000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2020-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -16054000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16054000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017022003991/virx-20211231.htm#2230835 Filing: 000095017022003991 The citation records this snapshot. The page link may show a newer release later.	USD 55,000 Exact value Exact value: 55000 USD 2020-01-01 – 2020-12-31: 55000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2020-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 55000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 55000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017022003991/virx-20211231.htm#2237968 Filing: 000095017022003991 The citation records this snapshot. The page link may show a newer release later.	−USD 16.11 million Calculation and evidence -16054000 − 55000 USD Exact free cash flow: -16109000 USD 2020-01-01 – 2020-12-31: -16054000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 55000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2020-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -16109000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16054000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017022003991/virx-20211231.htm#2230835 Filing: 000095017022003991 Input fundies:CapitalExpenditure: 55000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017022003991/virx-20211231.htm#2237968 Filing: 000095017022003991 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 114.76 million Exact value Exact value: -114762000 USD 2021-01-01 – 2021-12-31: -114762000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2021-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -114762000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -114762000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017023007905/virx-20221231.htm#2272392 Filing: 000095017023007905 The citation records this snapshot. The page link may show a newer release later.	−USD 18.85 million Exact value Exact value: -18851000 USD 2021-01-01 – 2021-12-31: -18851000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2021-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -18851000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18851000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017023007905/virx-20221231.htm#2338307 Filing: 000095017023007905 The citation records this snapshot. The page link may show a newer release later.	USD 252,000 Exact value Exact value: 252000 USD 2021-01-01 – 2021-12-31: 252000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2021-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 252000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 252000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017023007905/virx-20221231.htm#2346286 Filing: 000095017023007905 The citation records this snapshot. The page link may show a newer release later.	−USD 19.1 million Calculation and evidence -18851000 − 252000 USD Exact free cash flow: -19103000 USD 2021-01-01 – 2021-12-31: -18851000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 252000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2021-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -19103000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18851000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017023007905/virx-20221231.htm#2338307 Filing: 000095017023007905 Input fundies:CapitalExpenditure: 252000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017023007905/virx-20221231.htm#2346286 Filing: 000095017023007905 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 49.2 million Exact value Exact value: -49197000 USD 2022-01-01 – 2022-12-31: -49197000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2022-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -49197000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49197000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1573741 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	−USD 35.46 million Exact value Exact value: -35457000 USD 2022-01-01 – 2022-12-31: -35457000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2022-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -35457000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35457000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1603868 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	USD 45,000 Exact value Exact value: 45000 USD 2022-01-01 – 2022-12-31: 45000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2022-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 45000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 45000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1608689 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	−USD 35.5 million Calculation and evidence -35457000 − 45000 USD Exact free cash flow: -35502000 USD 2022-01-01 – 2022-12-31: -35457000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 45000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2022-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -35502000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35457000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1603868 Filing: 000095017024027982 Input fundies:CapitalExpenditure: 45000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1608689 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 51.06 million Exact value Exact value: -51058000 USD 2023-01-01 – 2023-12-31: -51058000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Net Income: -51058000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51058000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1572456 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	−USD 39.89 million Exact value Exact value: -39892000 USD 2023-01-01 – 2023-12-31: -39892000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Operating Cash Flow: -39892000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39892000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1602364 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	USD 138,000 Exact value Exact value: 138000 USD 2023-01-01 – 2023-12-31: 138000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Capital Expenditure: 138000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 138000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1607396 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.	−USD 40.03 million Calculation and evidence -39892000 − 138000 USD Exact free cash flow: -40030000 USD 2023-01-01 – 2023-12-31: -39892000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 138000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SUNESIS PHARMACEUTICALS INC · 2023-12-31 SUNESIS PHARMACEUTICALS INC (edgar:1061027) Free cash flow: -40030000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T14:12:06Z Snapshot: 1dfb72cb33c295b06db36abb47b4983ad843030eb1868753dd95ea6349710f84 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1061027?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39892000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1602364 Filing: 000095017024027982 Input fundies:CapitalExpenditure: 138000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1061027/000095017024027982/virx-20231231.htm#1607396 Filing: 000095017024027982 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

99 filings · 3,261 latest values · 3,261 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001061027, 1061027, SNSS, VIRX, edgar:1061027, snss

Also known as SUNESIS PHARMACEUTICALS INC, SUNESIS PHARMACEUTICALS INC., VIRACTA THERAPEUTICS, INC., Viracta Therapeutics, Inc.

SUNESIS PHARMACEUTICALS INC

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation